medwireNews articles

ESMO 2019 Congress

ESMO 2019 block

Find all medwireNews articles about results presented during the congress.

Date Title Topic
15 Oct 2019 Veliparib Combination Plus Maintenance Extends PFS For Advanced Serous Ovarian Carcinoma Ovarian Cancer - Personalised/Precision Medicine - Anticancer Agents
14 Oct 2019 Targeted Agent May Improve Survival For IDH1-Mutated Advanced Cholangiocarcinoma Hepatobiliary Cancers - Personalised/Precision Medicine - Anticancer Agents
11 Oct 2019 CASPIAN PROs Support Durvalumab Use For Extensive-Stage SCLC Small Cell Lung Cancer - Anticancer Agents - Immunotherapy
10 Oct 2019 BEACON CRC Triple Regimen Boosts BRAF V600E-Mutated Metastatic CRC Survival Colon and Rectal Cancer - Personalised/Precision Medicine - Anticancer Agents
09 Oct 2019 ATTRACTION-3 Confirms Nivolumab OS Benefit For Advanced Oesphageal Carcinoma Oesophageal Cancer - Anticancer Agents - Immunotherapy
08 Oct 2019 Cabazitaxel Benefit Demonstrated For metastatic CRPC Patients Prostate Cancer - Anticancer Agents
07 Oct 2019 PAOLA-1 Supports Olaparib–Bevacizumab Maintenance For HRD-Positive Advanced Ovarian Cancer Ovarian Cancer - Personalised/Precision Medicine - Anticancer Agents
03 Oct 2019 Olaparib May Have PROfound Effect On mCRPC Prostate Cancer - Personalised/Precision Medicine - Anticancer Agents
02 Oct 2019 FLAURA: First-Line OS Benefit Confirmed For Advanced EGFR-Mutated NSCLC Non-Small Cell Lung Cancer - Personalised/Precision Medicine - Anticancer Agents
01 Oct 2019 Pembrolizumab Shows Early Triple-Negative Breast Cancer Potential Breast Cancer - Anticancer Agents - Immunotherapy
30 Sep 2019 Abemaciclib Plus Fulvestrant Supported For HR-Positive, HER2-Negative Advanced Breast Cancer Breast Cancer - Anticancer Agents
29 Sep 2019 CheckMate 227 Further Supports First-Line Nivolumab–Ipilimumab For Advanced NSCLC Non-Small Cell Lung Cancer - Immunotherapy
28 Sep 2019 Advanced Melanoma Nivolumab–Ipilimumab Survival Benefit Lasts For 5 years Melanoma - Immunotherapy